手机电玩城游戏(澳门)股份公司-Maigoo百科

Dr. Luxia Liang

CEO

The pioneer and leading figure of local medical imaging CRO in China
18+ yrs of pharmaceutical industry experience
37+ yrs of radiological practice and research experience
600+ oversee 600+ global oncological trials

Curriculum Vitae & Research Experience

2012~present 10 yrs at FAB, Founder & CEO;
2005~2012 8 yrs at ICON, Sr. Med Dir. ;
2001~2005 Radiology, Duke Univ. Medical Ctr., USA;
1996~2001 Radiology, Kumamoto Univ, Japan;
1986~1996 Radiology, Southern Med Univ, China;

Specialised in oncology and central nervous system diseases
SCI publications in prestigious journal or book: over 20

Publications：

1.Luxia Liang, Yukunori Korogi, Takeshi Sugahara, Mitsukazu Onomichi, Yoshinori Shigematsu, Deweng Yang, Mika Kitajima, Toshinori Hiai and Mutsumasa Takahashi. Evaluation of the intracranial dural sinuses with 3D contrast-enhanced MP-RAGE sequence: prospective comparison with 2D-TOF MR venography and digital subtraction angiography. AJNR American Journal of Neuroradiology 2001, 22: 481-492. 2. Takeshi Sugahara, Yukunori Korogi, Masato Kochi, Ichiro Ikushima, Yoshinori Shigematsu, Toshinori Hirai, Tomoko Okuda, Luxia Liang, Yulin Ge, Yasuyuki Komohara, Yukitaka Ushio and Mutsumasa Takahashi. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. JMRI Journal of MagneticResonance Imaging 1999; 9:53-60. 3. Luxia Liang, Yukunori Korogi, Takeshi Sugahara, Ichoiro Ikushima, Yoshinori Shigematsu, Tomoko Okuda and Mutsumasa Takahashi. Dynamic MR imaging of neurohypophyseal germ cell tumors for differential diagnosis of infundibular diseases. Acta Radiology 2000; 41:562-566.

Dr. Jun Jiang

CMO

Department of Radiology, Cancer Hospital Chinese Academy of Medical Sciences Associate Chief Physician
10+ yrs of independent imaging assessment experience at FAB
20+ yrs of clinical trial research and tumor image evaluation and diagnosis related work
100+ participated in hundreds of clinical studies on lymphoma, colorectal cancer, gastric carcinoma, liver cancer, breast cancer, lung cancer and esophageal cancer. Several of these projects have submitted to NDA.

Clinical Experience

· One of the earliest industry practitioners in China, who began to serve as independent reading experts in 2012. Have participated in hundreds of clinical studies such as lung cancer, colorectal cancer, gastric cancer, liver cancer, breast cancer, esophageal cancer, and lymphoma, and have a very rich experience in imaging diagnosis and evaluation.
· Familiar with multiple efficacy evaluation criteria, especially RECIST1.1. Extensive experience in lung cancer project evaluation.
· A member of the Imaging Professional Group of multiple Cancer Associations of China. Published many papers on imaging diagnosis and evaluation of tumor diseases in China and abroad and won awards.

Dr. Yanping Chen

Chairman,Expert Advisory Committee

Imaging Center, Nanfang Hospital of Southern Medical University Chief Physician
9+ yrs of independent imaging assessment experience at FAB
38+ yrs of clinical experience in imaging
40+ participated in clinical trials for various diseases. Several of the drugs involved in imaging evaluations have been approved for marketing.

· Have participated in clinical trials for various diseases such as liver cancer, lung cancer, breast cancer, ovarian cancer, thyroid cancer, gastric carcinoma, colorectal cancer, head and neck squamous cell carcinomas and glioma, and have very rich experience in diagnostic imaging and evaluation.
· Over 40 years of clinical trial research and work related to tumor imaging assessment and diagnosis, mainly focusing on CT/MRI medical, teaching and research work, and have extensive clinical diagnostic and teaching experience in diagnostic imaging.
· Proficient in the use of several evaluation criteria and has been involved in the evaluation of several drugs that have been approved for marketing.
· Deputy director of Diagnostic Imaging Committee of Guangdong Liver Disease Society, head of Neurology Group of Guangdong Radiological Society and a member of Radiology Branch of Guangdong Medical Association.
· Published several papers on diagnostic imaging and evaluation of tumor diseases in China and abroad.

Abe Li

CTO

ITIL expert, Medifacts’ (Global Medical Consulting Services) technical director in Asia Pacific,Tigermed Senior IT Director. 23 years of IT industry experience, including 18 years of IT infrastructure management experience in CRO industry.

Aminy Tian

Director, Clinical Operations

8+ yrs of project management experience at FAB
12+ yrs of experience as a hospital imaging clinician with extensive imaging knowledge
100+ responsible for domestic and international projects, including lung cancer, breast cancer, colorectal cancer, liver cancer, cervical cancer, gastric cancer and other solid tumors as well as lymphoma projects. Several of these projects have submitted to NDA.

· Member of Radiological Society of North America (RSNA) and close communication with RSNA.
· Strong ability to control project risk and quality.
· Attended many investigator meetings and conducted imaging training for investigators.
· Responsible for the overall management of the drug projects which have then be marketed such as Hengrui Pyrrolitinib Breast Cancer, Hansoh Almonertinib Lung Cancer, and Allist Furmonertinib Lung Cancer. Strong ability to interpret and control various imaging evaluation criteria.
· Received the titles of "Excellent Manager" and "Excellent Project Leader" from Tigermed annually. Led the team to receive the "Excellent Team Contribution Award" from Tiger Group for many years.
· Praised by the Sponsor several times and received good comments from the sponsor.

Jing Hu

Associate Director, Clinical Operations

7+ yrs of project management experience at FAB
10+ yrs of clinical experience in imaging
50+ involved in managing research projects

· Graduated from Wan Nan Medical College with a degree in medical imaging and has 4 years of experience as a diagnostician in the radiology department of the PLA 903 Hospital.
· Involved in managing over 50 research projects in the areas of oncology, myelofibrosis, idiopathic pulmonary fibrosis, myocardial nucleus, device balloon, etc. Some of the projects under his charge have submitted to NDA, including Pralatrexate, MabThera (Rituximab Injection), Envafolimab Injection, Icaritin and Donafenib Tosilate Tablets for HCC have been approved for marketing.
· Familiar with the criteria for evaluating the efficacy of solid tumors and lymphomas. Excellent project and operational management skills, efficient execution, flexible control of timeline, professional medical imaging background, solid diagnostic imaging knowledge, proficient in basic operation of various imaging instruments and writing of imaging reports.
· Often received emails and letters of appreciation from sponsors, and has been awarded the title of "Excellent Project Leader" for many times.

Renzhi Lou

Associate Director, Clinical Operations

8+ yrs of project management experience at FAB
8+ participated in the management of central pathology
40+ involved in managing research projects

· Graduated from China Medical University.
· Over 7 years of project management experience at FAB.
· Involved in the management of over 40 oncology projects in the areas of lymphoma, solid tumors (liver, lung, breast, ovarian, gastric, colorectal, cervical), device ballooning, multiple myeloma, and Warthoglobulin macroglobulinemia, in the areas of central imaging and central pathology.
· Some of the projects under his charge have submitted to NDA. Serplulimab Injection self-developed by Henlius and Ripertamab Injection self-developed by Sinocelltech, which he fully manages, have been approved for marketing in 2022.